Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity-Reference-Cited by-同舟云学术

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Published:2011-04-22 Issue:1 Volume:129 Page:245-255
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wilhelm Scott M.,Dumas Jacques,Adnane Lila,Lynch Mark,Carter Christopher A.,Schütz Gunnar,Thierauch Karl-Heinz,Zopf Dieter

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Angiogenesis in cancer and other diseases;Carmeliet;Nature,2000

2. Vascular endothelial growth factor as a target for anticancer therapy;Ferrara;Oncologist,2004

3. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium;Fong;Nature,1995

4. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice;Shalaby;Nature,1995

5. Sorafenib;Hasskarl;Recent Results Cancer Res,2010

Cited by 1120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10

2. Inclusion complexes of regorafenib with beta- and gamma-cyclodextrin derivatives: In silico and in vitro studies;Journal of Molecular Liquids;2024-10

3. Ag(I)-NHC/TBHP promoted aqueous synthesis of some new quinoline-aromatic amides; Anti-proliferative, Anti-VEGFR-2 and Molecular docking studies;Journal of Molecular Structure;2024-10

4. Regorafenib enhances the efficacy of photodynamic therapy in hepatocellular carcinoma through MAPK signaling pathway suppression;Photodiagnosis and Photodynamic Therapy;2024-10

5. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma;Expert Opinion on Drug Metabolism & Toxicology;2024-09-03